Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Tax Provisions: 2019-2025

Historic Tax Provisions for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to $18.3 million.

  • Catalyst Pharmaceuticals' Tax Provisions rose 37.02% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.7 million, marking a year-over-year increase of 18.78%. This contributed to the annual value of $52.9 million for FY2024, which is 51.18% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Tax Provisions stood at $18.3 million, which was up 6.21% from $17.2 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Tax Provisions registered a high of $23.7 million during Q4 2023, and its lowest value of -$7.3 million during Q3 2023.
  • In the last 3 years, Catalyst Pharmaceuticals' Tax Provisions had a median value of $14.5 million in 2025 and averaged $12.5 million.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Tax Provisions soared by 506.69% in 2021, and later crashed by 322.68% in 2023.
  • Catalyst Pharmaceuticals' Tax Provisions (Quarterly) stood at $3.5 million in 2021, then soared by 115.10% to $7.5 million in 2022, then soared by 214.94% to $23.7 million in 2023, then declined by 21.02% to $18.7 million in 2024, then soared by 37.02% to $18.3 million in 2025.
  • Its Tax Provisions was $18.3 million in Q3 2025, compared to $17.2 million in Q2 2025 and $14.5 million in Q1 2025.